Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $74.2 million.

  • Viridian Therapeutics, Inc.\DE's Total Liabilities rose 1516.05% to $74.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year increase of 1516.05%. This contributed to the annual value of $70.8 million for FY2024, which is 4620.06% up from last year.
  • Viridian Therapeutics, Inc.\DE's Total Liabilities amounted to $74.2 million in Q3 2025, which was up 1516.05% from $67.2 million recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Total Liabilities peaked at $74.2 million during Q3 2025, and registered a low of $16.0 million during Q4 2021.
  • For the 5-year period, Viridian Therapeutics, Inc.\DE's Total Liabilities averaged around $41.4 million, with its median value being $40.0 million (2022).
  • Examining YoY changes over the last 5 years, Viridian Therapeutics, Inc.\DE's Total Liabilities showed a top increase of 15027.82% in 2022 and a maximum decrease of 184.75% in 2022.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Total Liabilities (Quarter) stood at $16.0 million in 2021, then skyrocketed by 150.28% to $40.0 million in 2022, then rose by 20.92% to $48.4 million in 2023, then skyrocketed by 46.2% to $70.8 million in 2024, then increased by 4.81% to $74.2 million in 2025.
  • Its Total Liabilities stands at $74.2 million for Q3 2025, versus $67.2 million for Q2 2025 and $56.5 million for Q1 2025.